Mirion Technologies (MIR)

What Moves the Stock

1. 01Nuclear power plant life extension and uprating projects - drives instrumentation upgrades and multi-year service contracts worth $2-5M per plant
2. 02Medical isotope production capacity additions - new Mo-99 production facilities and radiopharmaceutical manufacturing expansions require specialized detection equipment
3. 03Defense budget allocations for radiological/nuclear detection programs - border security portal deployments and military CBRN (chemical, biological, radiological, nuclear) equipment procurement
4. 04Acquisition announcements and integration execution - company has pursued roll-up strategy in fragmented radiation detection market
5. 05Nuclear decommissioning project awards - large-scale plant closures generate $10-30M equipment and services opportunities over 5-10 year timelines
6. 06Medical radiation detection systems (~40% of revenue) - dosimetry badges, area monitors, and sterilization equipment for hospitals and medical device manufacturers
7. 07Nuclear power plant instrumentation (~35% of revenue) - reactor monitoring systems, personnel dosimeters, and environmental surveillance equipment with recurring calibration services
8. 08Industrial and defense applications (~25% of revenue) - border security radiation portals, laboratory spectroscopy systems, and contamination detection for decommissioning projects

MIR Chart

My Notes

• growth - The stock attracts growth investors focused on nuclear energy renaissance themes, medical technology expansion…
• Rising rates create modest headwinds through higher financing costs on the company's $370M net debt position (0.68 debt/equity ratio)…
• Watch on earnings: Global nuclear power capacity additions and uprating announcements - indicates addressable market expansion particularly in China, India, and emerging markets, US Nuclear Regulatory Commission license renewal applications - 20-year extensions drive $3-5M instrumentation upgrade cycles per plant, Medical isotope supply chain developments - Mo-99 reactor outages or new production facilities impact demand for radiation detection in radiopharmaceutical manufacturing.